Literature DB >> 20039171

Churg-Strauss syndrome: retrospective study in Burgundian population in France in past 10 years.

Julien Vinit1, Géraldine Muller, Philip Bielefeld, Pierre Pfitzenmeyer, Philippe Bonniaud, Bernard Lorcerie, Jean-François Besancenot.   

Abstract

Churg-Strauss Syndrome (SCS) is a systemic vasculitis associated with asthma and eosinophilia. The aim of our work is to describe this pathology in the Burgundian population in France. We counted from the hospitalisation data-processing summaries, the whole of the SCS hospitalised in Burgundy between 1998 and 2008. During the follow-up, the clinical and paraclinical characteristics of every patient were collected. The average prevalence is of 11.3 per million inhabitants and the incidence is of 1.2 new cases per million inhabitants per annum. There exists however, a great prevalence disparity and incidence amongst the various departments of the area. The patient's average follow-up is of 7.7 years. In 23% of the cases one finds a starting factor for vasculitis. The delay between the first signs and the diagnostic is an average of 61 months. The ANCA are positive in 26% of cases and of anti-myeloperoxidase specificity in 83% of cases (P < 0.001). The most profitable biopsies are essentially cutaneous and neuromuscular. At the diagnostic, two-third of the patients have had a treatment adapted according to the current recommendations based on the Five Factor Score. The remission rate within a 1-year period is of 77%. The remission is strongly correlated to the therapeutic protocol associating corticoids and cyclophosphamide (P < 0.05). In conclusion, the prevalence of SCS in our area is similar to that observed in other European regions. However, this vasculitis remains a difficult and often a tardive diagnostic pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20039171     DOI: 10.1007/s00296-009-1275-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

Review 1.  Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants.

Authors:  A D Mahr; T Neogi; P A Merkel
Journal:  Clin Exp Rheumatol       Date:  2006 Mar-Apr       Impact factor: 4.473

2.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

Authors:  Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Véronique Le Guern; Marie-Hélène André; Martine Gayraud; David Jayne; Daniel Blöckmans; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2007-05-15

3.  Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients.

Authors:  Anne Bourgarit; Philippe Le Toumelin; Christian Pagnoux; Pascal Cohen; Alfred Mahr; Véronique Le Guern; Luc Mouthon; Loïc Guillevin
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

4.  Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre.

Authors:  A Della Rossa; C Baldini; A Tavoni; A Tognetti; D Neglia; G Sambuceti; R Puccini; C Colangelo; S Bombardieri
Journal:  Rheumatology (Oxford)       Date:  2002-11       Impact factor: 7.580

5.  No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register.

Authors:  E Reinhold-Keller; K Herlyn; R Wagner-Bastmeyer; J Gutfleisch; H H Peter; H H Raspe; W L Gross
Journal:  Rheumatology (Oxford)       Date:  2002-05       Impact factor: 7.580

6.  Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis.

Authors:  Thomas Neumann; Bernhard Manger; Michael Schmid; Claus Kroegel; Andreas Hansch; Werner A Kaiser; Dirk Reinhardt; Gunter Wolf; Gert Hein; Gerhard Mall; Georg Schett; Jochen Zwerina
Journal:  Medicine (Baltimore)       Date:  2009-07       Impact factor: 1.889

7.  Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register.

Authors:  Eva Reinhold-Keller; Karen Herlyn; Rosemarie Wagner-Bastmeyer; Wolfgang L Gross
Journal:  Arthritis Rheum       Date:  2005-02-15

8.  Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies.

Authors:  R M Martin; L V Wilton; R D Mann
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-05       Impact factor: 2.890

9.  Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.

Authors:  Karina A Keogh; Ulrich Specks
Journal:  Am J Med       Date:  2003-09       Impact factor: 4.965

10.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.

Authors:  Camillo Ribi; Pascal Cohen; Christian Pagnoux; Alfred Mahr; Jean-Pierre Arène; Dominique Lauque; Xavier Puéchal; Philippe Letellier; Philippe Delaval; Jean-François Cordier; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2008-02
View more
  2 in total

1.  Systematic Review and Metaanalysis of Worldwide Incidence and Prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis.

Authors:  Rocío Redondo-Rodriguez; Natalia Mena-Vázquez; Alba María Cabezas-Lucena; Sara Manrique-Arija; Arkaitz Mucientes; Antonio Fernández-Nebro
Journal:  J Clin Med       Date:  2022-05-04       Impact factor: 4.964

2.  Differential Diagnosis of Churg-Strauss Syndrome with Tingling Sensation and Weakness of the Lower Extremities.

Authors:  WooSeong Jeong; So Hui Yun; Jin Seok Kim
Journal:  Anesth Pain Med       Date:  2018-11-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.